ACON Aclarion, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ACON Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Health Information Services
Current Price
Live
$2.54
Analyst Target
$23.0
+805.5%
Upside
52W High
$229.5
52W Low
$2.34
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 21, 2026
Market cap
$2.68M
P/E
N/A
ROE
-97.7%
Profit margin
N/A
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
92%
Analysis Accuracy
ACON's deterministic health scores are severely compromised: the Piotroski F-Score of 1/9 indicates extreme financial distress, and the absence of an Altman Z-Score with negative profitability and negative cash flow signals high bankruptcy risk. Despite a 31.5% YoY revenue growth, the company exhibits catastrophic losses, with operating margins at -9,666.16% and ROE of -97.72%, rendering its valuation metrics meaningless. The stock trades at a price/sales of 39.69, far above peers, and has declined 98.2% over the past year, reflecting deep investor skepticism. The lack of analyst coverage and neutral insider activity further undermine confidence.
Key Strengths
31.5% year-over-year revenue growth suggests potential market traction
High current and quick ratios (17.01 and 16.31) indicate strong short-term liquidity
Recent quarterly earnings surprise improved from -345.4% to -11.0%, showing some margin improvement
Price is near 52-week low ($2.34), offering a potential entry point for speculative investors
One analyst maintains a $23.00 target price, indicating a long-term belief in recovery
Key Risks
Piotroski F-Score of 1/9 is among the weakest possible, signaling severe financial deterioration
Operating margin of -9,666.16% and ROE of -97.72% reflect unsustainable losses
No meaningful cash flow or profitability, with negative earnings and no free cash flow data
Price/Sales of 39.69 is extremely high relative to peers and fundamentals, indicating overvaluation
52-week high of $229.50 vs current $2.54 suggests a massive collapse in market confidence
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
12
Weak
10
35
10
5
0
AI Verdict
High Risk - Distressed
Key drivers: Piotroski F-Score of 1/9, Negative operating and net margins, No positive cash flow or profitability, Extreme price-to-sales multiple, 98.2% one-year decline
Confidence
95%
Value
10/100
Ref P/E, PEG, Graham Number
Positives
- Price near 52-week low ($2.34)
- High current ratio suggests liquidity cushion
Watchpoints
- Price/Sales of 39.69 is extremely high
- No Graham Number or intrinsic value available
- No P/E or PEG to anchor valuation
- Revenue growth does not offset massive losses
Future
35/100
Ref Growth rates
Positives
- 31.5% YoY revenue growth
- Improving earnings surprise trend (from -345% to -11%)
Watchpoints
- No forward P/E or earnings growth data
- Negative operating cash flow
- No free cash flow
- High risk of capital depletion
Past
10/100
Ref Historical trends
Positives
- Some improvement in earnings surprise over last 4 quarters
Watchpoints
- Consistently negative earnings with large misses
- Historical EPS growth of +99.8% is misleading due to negative base
- Massive swings in actual vs estimated earnings
- 5-year price change of -100%
Health
5/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- High current and quick ratios (17.01, 16.31)
Watchpoints
- Piotroski F-Score of 1/9 indicates severe financial distress
- No Altman Z-Score available, but negative ROE and margins suggest distress
- Negative ROA (-52.37%) and ROIC (N/A)
- No debt/equity data, but extreme losses imply high financial risk
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend yield and payout ratio are N/A
- No dividend declared or paid
- Negative earnings make dividend payment impossible
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.54
Analyst Target
$23.0
Upside/Downside
+805.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACON and closest competitors.
Updated 2026-02-20
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACON
Aclarion, Inc.
Primary
|
-100.0% | -100.0% | -98.2% | -65.2% | -34.0% | -1.6% |
|
AKAN
Akanda Corp.
Peer
|
-100.0% | -99.9% | -94.2% | -92.4% | -40.2% | +18.1% |
|
BDRX
Biodexa Pharmaceuticals Plc
Peer
|
-100.0% | -100.0% | -95.1% | -75.6% | -24.0% | -4.0% |
|
ADTX
Aditxt, Inc.
Peer
|
-100.0% | -100.0% | -100.0% | -99.6% | -65.3% | -17.8% |
|
BIAF
bioAffinity Technologies, Inc.
Peer
|
-99.5% | -98.4% | -92.9% | -86.5% | +9.8% | -1.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-0.19
PEG Ratio
N/A
P/B Ratio
0.12
P/S Ratio
39.69
EV/Revenue
-143.17
EV/EBITDA
1.45
Market Cap
$2.68M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-9666.16%
Gross Margin
-7.83%
ROE
-97.72%
ROA
-52.37%
Growth
Revenue and earnings growth rates
Revenue Growth
+31.5%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
17.01
Strong
Quick Ratio
16.31
Excellent
Cash/Share
$16.95
Quarterly Earnings History
EPS performance vs analyst estimates
2025-11-12
$-2.93
-11.0% surprise
2025-08-14
$-2.75
-21.6% surprise
2025-04-09
$-1628.09
-20.0% surprise
2024-11-14
$-1356.74
+16.7% surprise
Healthcare Sector Comparison
Comparing ACON against 146 companies in the Healthcare sector
(11 bullish, 60 neutral, 75 bearish)
Return on Equity (ROE)
-97.72%
This Stock
vs
-56.86%
Sector Avg
+71.8%
(Excellent)
Revenue Growth
31.5%
This Stock
vs
62.23%
Sector Avg
-49.4%
(Slower)
Current Ratio
17.01
This Stock
vs
3.45
Sector Avg
+393.2%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACON
Aclarion, Inc.
|
BEARISH | $2.68M | - | -97.7% | -% | $2.54 | |
|
AKAN
Akanda Corp.
|
BEARISH | $3.03M | 0.01 | -60.9% | -266.3% | $1.5 | |
|
BDRX
Biodexa Pharmaceuticals Plc
|
BEARISH | $1.8M | - | -61.8% | -% | $2.15 | |
|
ADTX
Aditxt, Inc.
|
BEARISH | $0.9M | - | -% | -% | $0.51 | |
|
BIAF
bioAffinity Technologies, Inc.
|
BEARISH | $6.07M | - | -245.2% | -217.5% | $1.35 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-26 | NESS BRENT | Chief Executive Officer | Purchase | 10 | $62 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
1 analysts
Ascendiant Capital
2025-11-20
Buy
Buy
Ascendiant Capital
2025-09-19
Buy
Buy
Past News Coverage
Recent headlines mentioning ACON from our newsroom.
Newest → oldest
No matching news yet.